EasyM: Blood-based MRD for MM

Heading into #ASCO25 we're happy to share our latest paper with the #myeloma community. Dr. Slade has been instrumental to helping EasyM develop its state-of-the art non-invasive #mmMRD assay and we look forward to the next ! EasyM is a CLIA certified LDT and not FDA approved

❤️ Making Myeloma Matter in Kitchener! We’re proud to be here together in our red EasyM shirts, raising awareness and showing support for those affected by multiple myeloma. Today, we’re participating in the Myeloma Canada Challenge, standing together, sharing our voices, and helping bring greater awareness to this disease. Together, we stand for patients, families, and the future. 💪 #MyelomaActionMonth #MoreThanMyeloma #MyelomaCanada #Kitchener #TeamEasyM #StrongerTogether #MultipleMyeloma #MM #MRD

🚨 Early Detection in Multiple Myeloma After CAR-T Therapy! A new study lead by Dr. Pasvolsky and colleagues at @UTMDAnderson shows that EasyM, a blood-based clonotypic mass spectrometry-based assay, can track minimal residual disease (MRD) in multiple myeloma patients receiving Ciltacabtagene Autoleucel (cilta-cel) with unprecedented sensitivity. Key Finding: EasyM spotted relapse 249 days before clinical progression, while traditional SPEP tests were still negative. This could help clinicians intervene earlier and tailor post-CAR-T monitoring. This is the first study using EasyM in the post-CAR-T setting, and the results are promising for improving disease surveillance. Read the full abstract: easym.com/mrd-monitoring… #MultipleMyeloma #CART #CiltaCel #MassSpectrometry #MRDMonitoring #Oncology #Hematology #MRD #MM #MMSM

🩸 Who is at higher risk for multiple myeloma? • Adults over 60 • Individuals of African Ancestry • Men (slightly higher risk than women) • People with a family history of blood cancers • Those diagnosed with MGUS (a precursor condition) Understanding these risk factors helps us advocate for earlier testing and monitoring, because knowledge is power. 💪 #MyelomaAwarenessMonth #MultipleMyeloma #MM #MRD #MMSM #Hematology #Oncology #BloodCancer

@rapidnovor has received a provisional license from the Ontario Ministry of Health for its @easym_test, a personalized, non-invasive blood test designed to track measurable residual disease for multiple myeloma. Find out more about Rapid Novor’s proprietary mass spectrometry-based protein sequencing technology ➡️ hubs.ly/Q046MR3K0

🚨 Breakthrough for Canadian Myeloma patients 🇨🇦 For the first time, blood-based MRD testing for multiple myeloma can be offered in Canada, by a Canadian company, for Canadian patients. Rapid Novor’s EasyM® MRD blood test for multiple myeloma has received a provisional license for use in Canada. Why it matters: - No invasive bone marrow biopsies - Frequent monitoring of disease kinetics - Detects disease beyond the marrow - Better access and simpler logistics 🔗 Full announcement: easym.com/rapid-novors-b… Thank you to the Canadian myeloma community advancing care every day: @MyelomaCanada @ResearchMyeloma @pmcancercentre #MultipleMyeloma #MMSM #MM #MRD #CanadianBiotech #Oncology #Hematology

Know the CRAB symptoms of multiple myeloma: 🦀 C - Calcium elevation (high calcium levels) 🦀 R - Renal (kidney) problems 🦀 A - Anemia 🦀 B - Bone pain or bone damage Learn more here: easym.com/types-of-multi… Awareness saves lives 💛 #MyelomaAwareness #CRABSymptoms #BloodCancer #MultipleMyeloma #MyelomaAwarenessMonth #KnowTheSigns #MM #MRD #Hematology #Oncology

What is Multiple Myeloma? Multiple myeloma is a cancer of plasma cells, a type of white blood cell found in the bone marrow. When these cells become cancerous, they multiply uncontrollably, crowding out healthy blood cells and weakening the body’s ability to fight infection. Myeloma cells can also cause bone damage and produce an abnormal protein called monoclonal protein (M-protein), which can harm the kidneys and interfere with normal immune function. Early awareness can make a difference. Learn the signs. Share the facts. 💛 Learn more here: easym.com/m-spike-and-mu… #MultipleMyeloma #MyelomaAwarenessMonth #KnowTheSigns #MM #MRD #Hematology #Oncology

Myeloma Awareness Month is here 📢 This month, we’ll be sharing important myeloma facts to help raise awareness and support those affected by this cancer🩸 Follow along all month as we highlight key information and resources. Together, we can spread knowledge and hope 💪 #MyelomaAwareness #BloodCancerAwareness #HealthEducation #MM #MRD #Myeloma #MultipleMyeloma

How well does clonotypic mass spectrometry (CT-MS) align with next-generation flow (NGF) for measuring minimal residual disease (MRD) in multiple myeloma (MM)? In Haematologica (Zhao et al., 2024), CT-MS blood-based MRD test was compared directly with EuroFlow (NGF) bone marrow-based MRD test. Key findings: • Blood-based CT-MS showed higher sensitivity than bone marrow/based EuroFlow (NGF) • Rising CT-MS levels predicted relapse, up to 38 months earlier in some patients. • Overall agreement was 72%, but MS+/NGF− discordance increased with deeper responses. • CT-MS shows promise for non-invasive, sequential MRD monitoring in MM. These results support an important concept: MRD assessment may not need to be confined to bone marrow. Read the full study here: easym.com/comparison-of-… @MonashUni #MRD #MultipleMyeloma #Hematology #EuroFlow #MassSpectrometry #MM #MMMRD #MMSM #Oncology #BloodTest

Beyond CR: A More Powerful Way to Read Trial Success 📣 The U.S. Food and Drug Administration (FDA) recently reinforced that Complete Response (CR) is a valid clinical trial endpoint. But here’s the real question for pharma and clinical teams: What happens when everyone in trial is VGPR/ CR? As we've seen in recent trials. In our latest dataset (from a small but highly informative clinical study), this graph shows something unique: EasyM can: - Prognosticate survival within the VGPR and CR cohorts - Identify meaningful biological differences beyond conventional response criteria - Provide signal where CR alone appears uniform This suggests that EasyM may offer more resolution than CR alone, helping tease out meaningful differences in response without waiting years for PFS readouts. For pharma teams looking to extract more value from early trials, that matters. Read the full study here: pubmed.ncbi.nlm.nih.gov/38170583/ DM us to incorporate EasyM into your clinical trial! #ClinicalTrials #Pharma #MRD #DrugDevelopment #Oncology #DrugDevelopment #TranslationalScience #MultipleMyeloma #MM #MMMRD #MMSM

#mmsm @Myeloma_Society #Cure Long term follow up of Forte trial Patients who achieved sustained MRD negativity at 5 year landmark analysis with 9-year OS of 96.3%

📰 According to @bdermanmd (@UofC) and Dr. @andrew02114 (@harvardmed), clonotypic mass spectrometry (CT-MS) advancing the monitoring of multiple myeloma: - CT-MS is up to 1,000× more sensitive than traditional SPEP/IFX - Detects minimal residual disease (MRD) in blood without bone marrow biopsies - Finds relapse months to years earlier than conventional tests - Tracks patient-specific monoclonal proteins for precise monitoring The authors note that CT-MS is now commercially available and can be used for prognostic and monitoring purposes. Read the full publication here: #tbl2" target="_blank" rel="nofollow noopener">sciencedirect.com/science/articl… #MultipleMyeloma #MRD #MMSM #MMMRD #PatientCare #CancerResearch #MassSpectrometry #PrecisionMedicine #Oncology #Hematology

🚨 New Research Update Oren Pasvolsky and colleagues at @MDAndersonNews are studying EasyM, a blood-based minimal residual disease (MRD) test, in patients with multiple myeloma treated with CAR-T cell therapy. Key Insight: In this study, EasyM detected disease recurrence more than 8 months before standard testing in one patient, suggesting it may help identify relapse earlier. 💡 Why it matters: Earlier detection after CAR-T therapy could help clinicians monitor patients more closely and make timely treatment decisions. 🔗 Read the abstract here: sciencedirect.com/science/articl… #MultipleMyeloma #CART #PatientCare #MRD #CancerResearch #TANDEM2026 #MassSpectrometry #PrecisionMedicine #MMSM #MM

🌟 EasyM Team Spotlight: Yenis Barrios, Lab Operations Specialist 🌟 We’re proud to shine the spotlight on Yenis, our dedicated Lab Operations Specialist at EasyM! Yenis is passionate about ensuring our laboratory runs smoothly and efficiently so that every test is handled with care, accuracy, and deep respect for the people behind it. She is committed to using our resources wisely while maintaining the highest standards of quality, because she knows that reliable results truly matter when it comes to a patient’s health. Her thoughtful approach and operational excellence help power the critical work we do each day. A few facts about Yenis: • She is driven by continuous improvement, always looking for ways to strengthen processes, enhance efficiency, and ensure everything in the lab runs exactly as it should. • Outside of work, Yenis is a proud mom raising curious, Latin speaking, instrument playing children. Her family is her constant source of motivation. She cherishes simple moments like playing ping-pong, cooking together, and teaching her children responsibility, independence, and care for others. Values that strongly influence how she approaches her work. • What motivates her daily is the balance of managing both home and lab life. She thrives on the challenges of improving systems and ensuring excellence, knowing that the work we do directly supports patient care and wellbeing. We’re grateful for Yenis’s dedication, heart, and leadership, and for the pride she brings to supporting our mission every single day. #TeamSpotlight #LabOperations #ClinicalResearch #MultipleMyeloma #HealthcareInnovation #WomenInSTEM #LifeAtEasyM

Could blood-based MRD testing help give multiple myeloma patients a break from treatment? A recent review by Paiva et al. in Nature Reviews Clinical Oncology suggests it might be possible. By combining bone marrow and blood tests for measurable residual disease (MRD), doctors can monitor patients more frequently and closely. This frequent monitoring helps identify patients with deep, sustained remission and could give both doctors and patients the confidence to safely consider treatment free periods. Why this matters: - Reduces side effects from ongoing treatment - Improves quality of life - Helps doctors track disease better and respond quickly if it returns Frequent blood based MRD testing could make living with multiple myeloma less burdensome, while maintaining careful, personalized oversight. Learn more: easym.com/review-mrd-cli… @NatRevClinOncol #MultipleMyeloma #MRD #MM #BloodTests #PatientCare #FunctionalCure #Oncology #Hematology #CancerResearch